Cognex Corp. (CGNX) Q3 2025 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 28, 2025. Cognex Corporation is a leading global provider of machine vision products and solutions used in manufacturing and distribution. The company operates as a single segment focused on machine vision technology, serving industries such as logistics, automotive, consumer electronics, and semiconductors.
Key Financial Metrics
| Metric | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Revenue | $276.9M | $234.7M | $742.0M | $684.8M |
| Gross Profit | $187.3M | $159.4M | $499.5M | $467.9M |
| Gross Margin | 68% | 68% | 67% | 68% |
| Operating Income | $57.8M | $31.6M | $127.3M | $84.2M |
| Net Income | $17.7M | $29.6M | $81.8M | $77.8M |
| Diluted EPS | $0.10 | $0.17 | $0.48 | $0.45 |
| Operating Cash Flow (9M) | $170.6M (vs. $97.7M prior year) | |||
| Cash & Investments | $600.3M (as of Sept 28, 2025) | |||
| Long-Term Debt | $0 |
Material Changes vs. Prior Period
- Revenue Growth: Q3 revenue increased 18% year-over-year, driven by growth in logistics and consumer electronics sectors. This includes approximately $13 million in one-time revenue from a new strategic channel partnership in medical lab automation.
- Operating Leverage: Operating income margin expanded to 21% in Q3 2025 from 13% in Q3 2024, as revenue growth outpaced a 1% increase in operating expenses.
- Net Income Decline: Despite higher operating income, net income decreased 40% in Q3 2025 compared to Q3 2024. This was primarily due to a $33.3 million discrete tax expense accrued in Q3 2025 related to the enactment of the "One Big Beautiful Bill Act" (OBBBA), which modified international tax provisions (GILTI/NCTI).
- Geographic Shifts: Revenue from the Americas and Europe grew significantly (27% and 30% respectively in Q3), while Greater China and Other Asia saw mixed results due to customer procurement shifts and timing differences.
Guidance, Outlook, and Risks
- Tax Legislation Impact: The OBBBA legislation is expected to result in a full-year cash tax benefit of $12 million to $15 million, primarily due to immediate expensing of R&D costs, though this does not directly lower the effective tax rate for the current period.
- Capital Allocation: The company repurchased 3.6 million shares for $126.2 million during the first nine months of 2025. Approximately $140 million remains available under the current $500 million repurchase program. A quarterly dividend of $0.080 was paid in Q3, and a subsequent dividend of $0.085 was declared on October 29, 2025.
- Liquidity: The company maintains a strong balance sheet with no long-term debt and $600.3 million in cash and investments. Management believes existing resources are sufficient for the next 12 months.
- Risks: Key risks include global economic conditions, supply chain disruptions, foreign currency fluctuations, and the impact of trade disputes and tariffs. The company also faces risks related to the integration of acquisitions and the ability to retain skilled employees.
Investor Verification Checklist
- Discrete Tax Charge: Verify the long-term impact of the $33.3 million OBBBA-related tax accrual on future effective tax rates and cash flows.
- One-Time Revenue: Assess the sustainability of the $13 million revenue boost from the medical lab automation partnership and its effect on future quarters.
- Geographic Mix: Monitor the shift in revenue mix from Greater China to Europe and the Americas, and the potential volatility associated with customer procurement changes.
- Stock Repurchases: Track the pace of share buybacks against the remaining $140 million authorization and the impact on diluted share count.
- Inventory Levels: Review inventory balances ($143.7M) against sales trends to ensure no significant obsolescence risks, particularly given the $42.6M in outstanding purchase commitments.